These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 14534855)

  • 1. Dexanabinol: a novel cannabinoid with neuroprotective properties.
    Darlington CL
    IDrugs; 2003 Oct; 6(10):976-9. PubMed ID: 14534855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexanabinol: dexanabinone, HU 211, PA 50211, PRS 211007, sinnabidol.
    Drugs R D; 2003; 4(3):185-7. PubMed ID: 12757406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexanabinol (HU-211) has a beneficial effect on axonal sprouting and survival after rat optic nerve crush injury.
    Zalish M; Lavie V
    Vision Res; 2003 Feb; 43(3):237-42. PubMed ID: 12535983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia.
    Leker RR; Shohami E; Abramsky O; Ovadia H
    J Neurol Sci; 1999 Jan; 162(2):114-9. PubMed ID: 10202976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of HU-211 as a neuroprotectant for ischemic brain damage.
    Biegon A; Joseph AB
    Neurol Res; 1995 Aug; 17(4):275-80. PubMed ID: 7477742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220.
    Gershkovich P; Qadri B; Yacovan A; Amselem S; Hoffman A
    Eur J Pharm Sci; 2007 Aug; 31(5):298-305. PubMed ID: 17560096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers.
    Brewster ME; Pop E; Foltz RL; Reuschel S; Griffith W; Amselem S; Biegon A
    Int J Clin Pharmacol Ther; 1997 Sep; 35(9):361-5. PubMed ID: 9314087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B).
    Jüttler E; Potrovita I; Tarabin V; Prinz S; Dong-Si T; Fink G; Schwaninger M
    Neuropharmacology; 2004 Sep; 47(4):580-92. PubMed ID: 15380375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial.
    Maas AI; Murray G; Henney H; Kassem N; Legrand V; Mangelus M; Muizelaar JP; Stocchetti N; Knoller N;
    Lancet Neurol; 2006 Jan; 5(1):38-45. PubMed ID: 16361021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
    Lipton SA; Gu Z; Nakamura T
    Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologically activated therapeutics for neuroprotection.
    Lipton SA
    Nat Rev Neurosci; 2007 Oct; 8(10):803-8. PubMed ID: 17882256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of dexanabinol and tempol in focal cerebral ischemia: is there a ceiling effect?
    Teichner A; Ovadia H; Lavie G; Leker RR
    Exp Neurol; 2003 Aug; 182(2):353-60. PubMed ID: 12895446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexanabinol as a treatment for traumatic brain injury: will another therapeutic promise be broken?
    Bedell EA; Prough DS
    Crit Care Med; 2002 Mar; 30(3):710-1. PubMed ID: 11990944
    [No Abstract]   [Full Text] [Related]  

  • 15. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis.
    Achiron A; Miron S; Lavie V; Margalit R; Biegon A
    J Neuroimmunol; 2000 Jan; 102(1):26-31. PubMed ID: 10626663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Derivatives of dexanabinol. II. Salts of amino acid esters containing tertiary and quaternary heterocyclic nitrogen with increased water-solubility.
    Pop E; Soti F; Brewster ME; Barenholz Y; Korablyov V; Mechoulam R; Nadler V; Biegon A
    Pharm Res; 1996 Mar; 13(3):469-75. PubMed ID: 8692744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial.
    Knoller N; Levi L; Shoshan I; Reichenthal E; Razon N; Rappaport ZH; Biegon A
    Crit Care Med; 2002 Mar; 30(3):548-54. PubMed ID: 11990913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A; Alfaro V
    Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant.
    Shohami E; Gallily R; Mechoulam R; Bass R; Ben-Hur T
    J Neuroimmunol; 1997 Feb; 72(2):169-77. PubMed ID: 9042110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.